AstraZeneca has set an ambitious target to reach $80 billion in total revenue by 2030, a significant increase from its 2023 revenue of $45.8 billion. This growth is expected to come from its existing portfolios in oncology, biopharmaceuticals, and rare diseases, along with the planned launch of 20 new medicines by the end of the decade. The company stated that many of these new drugs have the potential to generate over $5 billion in peak year revenues, contributing to sustained growth beyond 2030.
Pascal Soriot, CEO of AstraZeneca, highlighted this as a "new era of growth" and noted that the company successfully met its $45 billion revenue goal set a decade prior. AstraZeneca plans to maintain its commitment to research and development while improving productivity across the company to achieve a core operating margin in the mid-30s percentage range by 2026 and sustain it thereafter. The pharmaceutical giant is also investing in transformative new technologies to ensure long-term growth.
Analyst Derren Nathan of Hargreaves Lansdown acknowledged the "Herculean effort" required for this ambition given high failure rates in clinical trials but praised AstraZeneca's industry-leading execution. He noted the company's focus on maintaining profitability, targeting a mid-30s underlying operating margin by 2026, up from 32% in the previous year. Nathan suggested that if these targets are met, the current forward earning multiple of around 18 times would not be overly demanding.
AstraZeneca's strategy includes a continued focus on cancer and biopharmaceuticals, in addition to rare diseases, where it has increased investment. An example of a new drug in the pipeline is a "first in class" asthma treatment, currently in late-stage trials, which the company hopes will generate $4 billion in annual revenue. The company also aims for operating profits around $30 billion by 2030, a substantial jump from $8.2 billion in 2023.
Beyond financial targets, AstraZeneca is also committed to environmental sustainability, aiming to decouple carbon emissions from revenue growth. The company has already reduced its greenhouse gas emissions (Scopes 1 and 2) by 68% from its 2015 baseline while increasing total revenue by 85% over the same period. It plans to be carbon zero for Scope 1 and 2 emissions by 2026 and halve Scope 3 emissions by 2030, working towards science-based net zero by 2045.
